Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:29 PM
Ignite Modification Date: 2025-12-24 @ 10:29 PM
NCT ID: NCT05324735
Eligibility Criteria: Inclusion Criteria: * Provide written, voluntary informed consent prior to study enrollment. * Male or female between the ages of 18 to 65. * Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-IV) criteria for bipolar I or II, currently experiencing a major depressive episode. A Mini-International Neuropsychiatric Interview (MINI) conducted by physician was used to confirm the diagnosis. * Meets the criteria for treatment resistant depression (TRD) defined by failure to respond to of at least two treatment trials (antidepressant regimen or electroconvulsive therapy) during the current depressive episode. * Prior to taking part in the trial, all patients were requested to be antidepressant free for 4 weeks or to be on a fixed psychotropic therapeutic regimen for at least 4 weeks. Exclusion Criteria: * Current psychotic symptoms or perceptual problems. * The presence of a contraindication to PTX, such as a drug allergy or xanthine derivative allergy. * Patients with substance dependence or abuse. * Patients with concurrent active medical condition (congestive heart failure, abnormal electrocardiogram, malignancy, schizophrenia, neurological disease). * Patients with inflammatory disorders and/or auto-immune conditions (rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, lupus)
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 65 Years
Study: NCT05324735
Study Brief:
Protocol Section: NCT05324735